WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 2-Jul-2015 (Data received as of 26-June-2015)
Next overall update Mid July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 82
GDP / capita (US$): 43'8241 Child (under 5 years) mortality rate: 102

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 1'344  1'332  1'318  1'293  1'252  668  496  360 
Births 20  20  20  20  20  15  14  12 
Surviving infants 20  20  20  20  19  14  14  11 
Pop. less than 5 years 106  103  98  94  90  72  66  50 
Pop. less than 15 years 287  280  272  262  249  206  162  124 
Female 15-49 years 305  304  303  300  294  162  113  75 

Number of reported case

(Click for retrospective incidence data for Bahrain)
Diphtheria
Japanese encephalitis
Measles 46  59  1'861 
Mumps 21  59  29  18  46  167 
Pertussis 106 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Bahrain)
Vaccine year result method % card seen                                                
BCG          99*  99*  87  73  81  63 
DTP1 1994  99     82  98  99  99*  99  99*  98 
DTP3 1994  90     82  99  99  99  99*  99*  97  94  92 
HepB_BD          99*  99  99*  99* 
HepB3 1994  88     82  99  99  99  99*  99*  97 
Hib3          99  99  99  99*  99*  97 
JapEnc         
MCV          99*  99*  99*  99*  99*  98  87  63 
MCV2          99*  99*  99*  96  98  92 
PCV1          99  99*  99*  99*  99* 
PCV3          98  99*  99  99*  99* 
Pol3 1994  90     82  99  99  99  99*  99*  97  94  92 
Rota1          98  98  99  97  71 
Rota_last          97  97  96  96  59 
Rubella1          99*  99*  99* 
TT2plus          30  38  36  40  59  71  41 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Bahrain)
DTP1 99  99  99  99  98  97  89 
DTP3 99  99  99  99  97  94  72 
HepB3 99  99  99  99  97 
HepB_BD
Hib3 99  99  99  99  97 
MCV 99  99  99  99  98  87  45 
MCV2 99  99  96  98  92 
PAB 94  94  94  94  84  48 
PCV3 99  99  99  99 
Pol3 99  99  99  99  97  94  72 
Rota_last 97  96  96  59 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes infants born to parents originally from TB endemic area
DT 2, 4, 6, 18 months; 5 years; Yes Children with contraindications or allergic to Pertussis componant of the vaccine
DTaP 5 years; Yes Preschool vaccination
DTaPHibHepIPV 2 months; Yes
DTwPHibHepB 4, 6, 18 months; Yes
HIB > 5 years; Yes Given as single dose for >5 years children with sickle cell disease, anatomical and/or surgical asplenia, post bone marrow transplant & certain cancer after finishing treatment;
HPV Yes available only in the private sector
HepA 18 months; 2 years; Yes and Catch up Vaccination for 12&13 yrs
HepB Birth; 1 month; Yes Hep B for Newborns of HBsAg positive mothers or unknwon HBsAg status and adults at risk and college students
IPV 2, 4, 6, 18 months; 5 years; Yes For immunocompromized and their household
Influenza Children; elderly; risk groups Yes and healthcare workers, obese, residents of nursing homes& other long term facilities , household of high risks of flu complications, offered to any one requesting the vaccine
MMR 1, 5 years; Yes for MMR campaigns
MenACWY 2 years; Yes
OPV 4, 6, 18 months; 5 years; Yes traveller to polio endemic countries
Pneumo_conj 2, 4, 6 months; 1 year; Yes as a single dose for those at 50 years of age and above
Pneumo_ps >=65 years; Yes routinely for those at age of 65 yrs and above & High Risk Groups from age of 2 years and above
Rotavirus 2, 4 months; Yes
Td >10 years; Yes Pregnant women, Post trauma, certain occupations at risk &Haj pilgrims, others at risk of exposure
Tdap 13 years; Yes School students Vaccination, elderly and other at risk.
Typhoid Yes Travellers, certain occupations at risk
Varicella Yes given as two doses to high risk groups and their household, Health care workers
YF Yes Travellers

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2017  2013-2015  2012-2015      2006-2012   
Nº of districts with microplans that include activities to raise immunization coverage number      

System performance

Total Nº districts in country number  
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100    100 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100  100  100    100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100  100        100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.